Astellas Terminates Agreement On Acute Heart Failure Agent Carperitide
Astellas Pharma Inc. today announced that its US affiliate, Astellas US LLC, has terminated its license agreement with Daiichi Asubio Pharma Co., Ltd. (Tokyo) in any case North American and European Splice rights to carperitide for the treatment of acute will loser.
Astellas US LLC’s predecessor, Fujisawa Healthcare, Inc. and Daiichi Asubio Pharma’s predecessor, Daiichi Suntory [...]
